Genmab A/S ADS (GMAB) Stock: Buy, Sell, or Hold?
$51.74
-2.13 (-3.95%)
âŧ
5d:
-1.9%
30d:
+40.25%
90d:
+61.99%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (41%)
Quality Score
33/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$37.34 â $53.71
Position: SLIGHTLY HIGH
Forward P/E & Valuation
29.3x
STRETCHED
vs 19.0x historical avg
Wall Street Target
$65.11
+25.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$51.22 / $59.02
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: GMAB is fairly priced but lacks strong directional signals. At 15.6% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$65.24
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$40.51
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $51.74, which is considered slightly high relative to its 30-day fair value range of $37.34 to $53.71. From a valuation perspective, the stock is trading at a premium (Forward PE: 29.3) compared to its historical average (19.0). At these levels, the market is pricing in 15.6% annual earnings growth.
Technical Outlook: Technically, GMAB is in a strong uptrend. The price is currently testing key support at $51.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: GMAB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $65.11 (+25.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMAB is in a strong uptrend. The price is currently testing key support at $51.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: GMAB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $65.11 (+25.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$37.34 -
$53.71
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
41.4%
Trading Range & Key Levels
30-Day Trading Range
$37.34 -
$53.71
Current vs Trading Range
SLIGHTLY HIGH
Support Level
$51.22
Resistance Level
$59.02
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 25.8% below Wall St target ($65.11)
- BULLISH: Expecting earnings turnaround to 15.6% growth with 16.1% revenue growth
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
29.34
Wall Street Target
$65.11
(+25.8%)
Revenue Growth (YoY)
16.1%
Earnings Growth (YoY)
-14.7%
Profit Margin
17.0%
Valuation Premium vs History
+15.6% premium
PE vs Historical
29.3 vs 19.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.6%
(market-implied from PE analysis)
1-Year Target
$59.81
(+16%)
2-Year Target
$69.14
(+34%)
3-Year Target
$79.93
(+55%)
3-Yr Target (if PE normalizes)
(PE: 29â19)
PE COMPRESSION
$51.76
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 29.3, Growth: 41.2%)
$145.55
(+181%)
Base:
(SPY PE: 19.9, Growth: 41.2%)
$98.51
(+90%)
Bear:
(PE: 16.9, Growth: 41.2%)
$83.74
(+62%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 46.04 | Current EPS (TTM): $1.17
Bull Case
$89.31
(+73%)
Analyst growth 50.7%, PE expands to 50.7
Base Case
$81.19
(+57%)
Market implied 50.7%, PE stable at 46.0
Bear Case
$36.63
(-29%)
Severe decline -20.0%, PE contracts to 39.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share GMAB Analysis
Share this live GMAB analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (GMAB)
Bullish
1 Retail Mentions
Reddit / WSB Comments
1
Bullish
Last Tracked
Jun 15, 2026
Daily AI digest
AI Retail Discussion Summary:
Reddit & WallStreetBets discussions on GMAB are bullish (sentiment score +0.40) across 1 tracked comments.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 4:25 AM ET
Data refreshes hourly during market hours. Next update: 5:25 AM
Data refreshes hourly during market hours. Next update: 5:25 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive GMAB Research Pages
